-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Enterprise News] Recently, Kelun Pharmaceutical disclosed the revision announcement of the 2022 semi-annual performance foreca.
Previously, in the first quarterly report of 2022, the company's forecast for the operating performance from January to June 2022 was: profit of 665 million yuan to 764 million yuan, an increase of 35% to 55% over the same period last ye.
The revised forecast is a profit of 820 million-890 million yuan, an increase of 639%-859% over the same period of the previous ye.
Regarding the reasons for the revision of the performance, the announcement stated that the company's holding subsidiary, Kerun Botai, has exclusively licensed its biological macromolecular tumor project A with independent intellectual property rights to MSD for research, development, manufacturing and business outside Chi.
chang.
According to the contract, according to the preliminary calculation of the contract obligations that Colombo has performed, the above matters will increase the net profit attributable to the parent company by about 120 million yu.
It is understood that this authorization transaction took place on May 13, when Colombo and Merck signed an agreement to pay a down payment of US$47 million for the rights outside Greater China of the biological macromolecular tumor project A with independent intellectual property rights ( and up to $363 billion in milestone payments and royalties on post-market net sales) licensed to Mer.
According to the reminder announcement issued by Kelun Pharmaceutical on June 28 on the receipt of MSD payment by the holding subsidiary, Kelun Botai has received the payment of USD 30 million from MSD on June 24, 2022 (the actual amount received Tax withholding and bank charges calculated in accordance with the relevant laws are deducte.
It is worth mentioning that the down payment of this transaction ranked first in the transaction amount of domestic new drugs going overseas in the first half of this ye.
Although the company has not disclosed the specific product, the industry speculates that it is probably SKB2
SKB264 is an antibody-drug conjugate (TROP2- AD.
On June 29, 2022, the product is planned to be included in the breakthrough therapy category, and the proposed indication is locally advanced or metastatic triple-negative breast cancer (TNB.
Relevant information shows that SKB264 directly targets the connected novel toxin molecules to tumor cells through TROP2 monoclonal antibody, which can effectively reduce the off-target toxicity of the drug, while taking into account the efficacy and safe.
Up to now, SKB264 has submitted at least 5 clinical trial applications (INDs), 3 of which have been approved by the National Medical Products Administration of China, including monotherapy for the treatment of advanced solid tumors, SKB264 combined with KL-A167 for the treatment of advanced solid tumors, respectively Or metastatic non-small cell lung cancer and triple-negative breast cancer, a single-agent phase III registration clinical trial for patients with advanced or metastatic triple-negative breast cancer who have failed at least second-line thera.
At present, SKB264 is rapidly progressing to Phase III clinical trials in Chi.
TROP2 has become a popular track for ADC drug layout, but currently only Immunomedics' Goxatuzumab (Trodelvy) has been approved for marketi.
Satuzumab, Trodelvy was successfully approved in China in June 2022, becoming the first approved TROP-2 ADC drug in Chi.
On the same track, AstraZeneca and Daiichi Sankyo reached an agreement in July 2022 to jointly develop the TROP2-ADC drug DS-106In general, behind the layout of many domestic and foreign pharmaceutical companies, the potential of TROP2-ADC is being optimistic about the indust.
Kelun Pharmaceutical's SKB264 was previously considered by the industry to be the first domestically produced TROP2-A.
I believe that it can further benefit the majority of patien.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Previously, in the first quarterly report of 2022, the company's forecast for the operating performance from January to June 2022 was: profit of 665 million yuan to 764 million yuan, an increase of 35% to 55% over the same period last ye.
The revised forecast is a profit of 820 million-890 million yuan, an increase of 639%-859% over the same period of the previous ye.
Regarding the reasons for the revision of the performance, the announcement stated that the company's holding subsidiary, Kerun Botai, has exclusively licensed its biological macromolecular tumor project A with independent intellectual property rights to MSD for research, development, manufacturing and business outside Chi.
chang.
According to the contract, according to the preliminary calculation of the contract obligations that Colombo has performed, the above matters will increase the net profit attributable to the parent company by about 120 million yu.
It is understood that this authorization transaction took place on May 13, when Colombo and Merck signed an agreement to pay a down payment of US$47 million for the rights outside Greater China of the biological macromolecular tumor project A with independent intellectual property rights ( and up to $363 billion in milestone payments and royalties on post-market net sales) licensed to Mer.
According to the reminder announcement issued by Kelun Pharmaceutical on June 28 on the receipt of MSD payment by the holding subsidiary, Kelun Botai has received the payment of USD 30 million from MSD on June 24, 2022 (the actual amount received Tax withholding and bank charges calculated in accordance with the relevant laws are deducte.
It is worth mentioning that the down payment of this transaction ranked first in the transaction amount of domestic new drugs going overseas in the first half of this ye.
Although the company has not disclosed the specific product, the industry speculates that it is probably SKB2
SKB264 is an antibody-drug conjugate (TROP2- AD.
On June 29, 2022, the product is planned to be included in the breakthrough therapy category, and the proposed indication is locally advanced or metastatic triple-negative breast cancer (TNB.
Relevant information shows that SKB264 directly targets the connected novel toxin molecules to tumor cells through TROP2 monoclonal antibody, which can effectively reduce the off-target toxicity of the drug, while taking into account the efficacy and safe.
Up to now, SKB264 has submitted at least 5 clinical trial applications (INDs), 3 of which have been approved by the National Medical Products Administration of China, including monotherapy for the treatment of advanced solid tumors, SKB264 combined with KL-A167 for the treatment of advanced solid tumors, respectively Or metastatic non-small cell lung cancer and triple-negative breast cancer, a single-agent phase III registration clinical trial for patients with advanced or metastatic triple-negative breast cancer who have failed at least second-line thera.
At present, SKB264 is rapidly progressing to Phase III clinical trials in Chi.
TROP2 has become a popular track for ADC drug layout, but currently only Immunomedics' Goxatuzumab (Trodelvy) has been approved for marketi.
Satuzumab, Trodelvy was successfully approved in China in June 2022, becoming the first approved TROP-2 ADC drug in Chi.
On the same track, AstraZeneca and Daiichi Sankyo reached an agreement in July 2022 to jointly develop the TROP2-ADC drug DS-106In general, behind the layout of many domestic and foreign pharmaceutical companies, the potential of TROP2-ADC is being optimistic about the indust.
Kelun Pharmaceutical's SKB264 was previously considered by the industry to be the first domestically produced TROP2-A.
I believe that it can further benefit the majority of patien.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
